News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

Participants of the Innovation for Health congress

02/25/2020 | BioRegio STERN Management GmbH

Innovation for Health – Codex4SMEs break-out session

A healthy future with good and affordable healthcare demands smart solutions. But those types of solutions don´t just appear out of thin air. To realise this, you need people with ground breaking ideas, energy, perseverance and a relentless belief in the added value represented by collaborations. You could find these kind of people at the Innovatio...

02/20/2020 | immatics biotechnologies GmbH

Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies

GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies Immatics to receive €45 Million (~$50 Million) upfront payment with potential for additional milestone and royalty payments

02/06/2020 | Curetis GmbH

Curetis and Quaphaco Enter into Unyvero Distribution Partnership for Vietnam

Exclusive distribution agreement for initial term of 3 years Quaphaco commits to minimum purchase totaling about EUR 1.9 million during initial term     

02/04/2020 | Ovesco Endoscopy AG

EFTR is a fast, safe and effective option for rectal NETs < 20 mm

In 40 patients with rectal neuroendocrine tumors (NETs), EFTR resulted in 100 % macroscopically and histologically complete resection. Median procedure time was 18.5 minutes. No major adverse events occurred.

02/04/2020 | CeGaT GmbH

CeGaT Brings New Dimension to Exome Diagnostics

CeGaT aims to solve all genetically-caused cases of disease to help physicians state a diagnosis. To pursue this goal, CeGaT incorporated its long-term expertise and latest scientific knowledge in an innovative diagnostic tool: CeGaT Exome Xtra is the most powerful genetic diagnostic option for patients with complex, unspecific, and rare diseases. ...

Bundesforschungsministerin Anja Karliczek steht in einem großen Raum. Vor ihr befinden sich fünf Mikrofone um ihr Statement aufzunehmen.

01/31/2020 | CureVac AG

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019

TÜBINGEN, Germany/ BOSTON, USA / OSLO, Norway January 31, 2020 – CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, and the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership set up to accelerate development of vaccines against emerging infectious diseases, today announ...

01/21/2020 | HepaRegeniX GmbH

HepaRegeniX GmbH secures Series B Financing in excess of €11 Mio. to advance first drug candidate to the clinic

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models

01/15/2020 | Ovesco Endoscopy AG

Ovesco Endoscopy awarded FOCUS Growth Champion 2020

Ovesco has been able to achieve a large growth in turnover and employees in recent years. Among 12,000 businesses nationwide surveyed by FOCUS-Business, the medical technology company has now been awarded the title of „FOCUS Wachstumschampion 2020“ (FOCUS Growth Champion 2020).

01/09/2020 | Atriva Therapeutics GmbH

Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week

Tübingen (Germany), January 8, 2020 – Atriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January.

01/07/2020 | CureVac AG

CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study

Low dose vaccination induced immune response in all subjects and was well tolerated Clinical results underline potency of CureVac’s technology platform Detailed results to be presented at an upcoming scientific conference    

12/20/2019 | Curetis GmbH

Curetis Receives U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

Broad Unyvero LRT BAL panel also includes atypical pathogens such as Pneumocystis jirovecii Clearance expected to substantially increase total addressable market for Unyvero System in the U.S. Commercial launch in the U.S. expected for Q1-2020

12/19/2019 | CureVac AG

Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research term Genmab will provide CureVac with a USD 10 million upfront payment and make an equity investment in CureVac of 20 million euro CureVac eligible to rece...

12/03/2019 | Eberhard Karls Universität Tübingen

Fungus produces active agent in a medicinal herb

Tübingen and Dresden researchers discover that a fungus in Tatarinow’s aster produces bioactive agents

12/02/2019 | CureVac AG

CureVac Granted Manufacturing Authorization for its Third GMP Production Suite

CureVac’s GMP I, II and III Combined Production Suite Scales Up Capacity to Meet All Preclinical, Clinical and Early Launch Needs for Proprietary and Partnered Programs

11/28/2019 | Ovesco Endoscopy AG

EFTR is a useful tool for staging of early colorectal cancer and simultaneously can be sufficient treatment for low-risk lesions

In 156 patients with histologic evidence of adenocarcinoma, EFTR was technically successful in 92.3 % and R0 resection was achieved in 71.8 %. Exact risk stratification was possible in 99.3 %. Severe procedure-related adverse events were recorded in 3.9 % of patients.

11/25/2019 | Curetis GmbH

Curetis Group Company Ares Genetics Wins MERCUR Innovation Prize

Vienna, Austria,and Holzgerlingen, Germany, November 25, 2019, 10:00 am CET-Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Geneticswas awarded the 2019 MERCUR Innovation Prize by the Vienna Economic Chamber in...

11/08/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial

Tübingen (Germany), November 08, 2019 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the successful conclusion and top-line results of its Phase I clinical trial for its lead drug candidate ATR-002. The official report will be released in January 2020.

10/31/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics to present at the BIO-Europe in Hamburg

Tübingen (Germany), October 31, 2019 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, will present at the upcoming 25th Annual International Partnering Conference BIO-Europe®.

Handshake between Michael J. Collins (CEM) and Dr. Steffen Huettner (Intavis).

10/29/2019 | Intavis AG

CEM Corporation acquires key assets of Intavis Bioanalytical Instruments

Matthews, N.C. October 25th, 2019 – CEM Corporation today announced that it has entered into a definitive agreement to purchase the instrumentation lines of Intavis Bioanalytical Instruments AG, with headquarters in Cologne Germany. The acquisition allows CEM to strengthen its product offering in the Life Sciences for proteomics, in-situ hybridizat...

10/28/2019 | Curetis GmbH

Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular antibiotic sus...